

- Thyrotropin-releasing hormone (TRH), 401e-2, 401e-4
- Thyroxine (T₄)
 characteristics of, 2286f
 free, 2286, 2288
 half-life of, 400e-2
 laboratory evaluation of, 2286f, 2288, 2763t
 in pregnancy, 124e-4, 124e-5t
 receptor binding of, 2287, 2287f
 in sick euthyroid syndrome, 2299
 structure of, 2283f
 in subacute thyroiditis, 2298–2299, 2298f
 total, 2288
 transport and metabolism of, 2285–2286
- Thyroxine-binding globulin (TBG), 2285, 2286, 2286t, 2288
- Thyroxine-binding prealbumin. *See* Transthyretin
- Thyroxine therapy
 for adult hypopituitarism, 2259t
 adverse effects of, 254
 for hypothyroidism in pregnancy, 49
- TIA. *See* Transient ischemic attack (TIA)
- Tiagabine
 adverse effects of, 2555t
 for anxiety disorders, 2711
 for epilepsy, 2555t
 overdosage/poisoning with, 473e-10t
 for stiff-person syndrome, 618
- Tibetan medicine, 14e-1t
- Tibia, Paget's disease of, 436e-3f
- Tibial muscular dystrophy (Udd's distal myopathy), 462e-12, 462e-13t
- Tic(s), 2619t, 2623
- Ticagrelor
 action of, 747
 adverse effects of, 748
 for cardiac catheterization pretreatment, 1461
 dosage of, 748
 indications for, 747–748
 for ischemic heart disease, 1590
 management before endoscopic procedures, 1889t
 for myocardial infarction, 1596, 1598, 1598t, 1606
 in PCI, 296e-1, 296e-2
- Ticarcillin, 306
- Ticarcillin-clavulanate
 for anaerobic bacterial infections, 1101t
 for bite-wound infections, 167e-2
 indications for, 938
 for peritonitis, 848
 resistance to, 1101
 for *S. maltophilia* infection, 1045t
- Tic douloureux. *See* Trigeminal neuralgia
- Tick(s)
Amblyomma spp., 1152, 1154
 bite characteristics of, 2745
Ixodes. *See* *Ixodes* spp. ticks
 Lyme disease prophylaxis following bite, 1153, 2745
Ornithodoros spp., 1146, 1147f
 removal of, 2745
 in Rocky Mountain spotted fever, 1154
- Tick-borne diseases
Babesia infections. *See* *Babesia* spp. infections
 Colorado tick fever, 1306t, 1319
 Crimean-Congo hemorrhagic fever, 1308t, 1321
 ehrlichioses, 1155t, 1159–1160, 1159f
 encephalitis, 1307t, 1315–1316
 human granulocytic anaplasmosis, 1152, 1155t, 1159f, 1160–1161
 Lyme borreliosis. *See* Lyme borreliosis (Lyme disease)
 relapsing fever. *See* Relapsing fever rickettsial. *See* Rickettsial diseases
 Rocky Mountain spotted fever. *See* Rocky Mountain spotted fever (RMSF)
 Southern tick-associated rash illness, 129t, 134, 1152
 tick-borne lymphadenopathy, 1155t
 tick granuloma, 2745
 tick paralysis, 989, 2745
- Ticlopidine
 action of, 746f
 adverse effects of, 729, 1864, 2218t, 2569
 management of
 before endoscopic procedures, 1889t
 before lumbar puncture, 443e-1
 for stroke/TIA prevention, 2569–2570
- Tie2, 102e-14f, 102e-15
- Tietze syndrome, 2246
- TIG (tetanus immune globulin), 167e-3, 986
- Tigecycline
 for *Acinetobacter* infections, 1037, 1037t
 action of, 930, 931t, 943, 1027
 adverse effects of, 943
 for anaerobic bacterial infections, 1101
 distribution of, 935
 for *Enterobacter* infections, 1034
 indications for, 940t, 943
 for *Klebsiella* infections, 1033
 for *Legionella* infections, 1020, 1020t
 for *Nocardia* infections, 1087
 in pregnancy and lactation, 937t
 resistance to
 in *Acinetobacter*, 1037
 in anaerobic bacteria, 1101
 in gram-negative bacteria, 1026, 1027
 mechanisms of, 931t, 934
 rates of, 940t
 for staphylococcal infections, 962
- Tiger snakes, 2734. *See also* Snakebites
- “Tight-building” syndrome, 1693
- Tight epithelia, 332e-3
- Tight junction, 332e-3
- Tilt table test, 148, 2641, 2641t
- Tiludronate, 426e-3, 426e-3t
- Time-of-flight (TOF) imaging, 440e-7
- TIMI (Thrombolysis in Myocardial Infarction) trial
 frame count, 1605
 grading system, 1605
 risk score, 1595, 1596f
- Timolol
 adverse effects of, 1671
 genetic variations in response to, 39t, 40
 for ischemic heart disease, 1589t
 metabolism of, 34t
 overdosage/poisoning with, 473e-9t
- Tincture of opium, 272
- Tinea, 353, 353t, 355, 1357, 1358t. *See also* Dermatophytosis
- Tinea capitis
 alopecia in, 354, 355t
 clinical features of, 355t, 1357
 diagnosis of, 343
- Tinea corporis, 76e-10f, 349, 1357
- Tinea cruris, 342f, 350, 1357
- Tinea manuum, 76e-10f
- Tinea pedis, 76e-10f, 342f, 350, 1357
- Tinea unguium, 76e-10f, 350
- Tinea versicolor, 350
 clinical features of, 341t, 350, 350t, 357, 357t, 358t, 1357
 diagnosis of, 341, 344, 358t
 etiology of, 350, 350t
 treatment of, 350, 350t, 358t, 1357
- Tinel's sign, 2221
- Tin exposure, 472e-3
- Tingling, 158. *See also* Sensation
- Tinidazole
 action of, 246e-13
 adverse effects of, 246e-5t
 for amebiasis, 1367, 1367t
 for bacterial vaginosis, 875
 drug interactions of, 246e-5t
 for *Giardia* infections, 1406
 in *H. pylori* eradication, 1042t
 pharmacology of, 246e-13
 in pregnancy and lactation, 246e-5t
 for *T. vaginalis* infections, 871, 873t, 1409
- Tinnitus, 220, 224, 2586
- Tinnitus masker, 224
- TINU (tubulointerstitial nephritis with uveitis), 1857–1858, 1858f
- Tinzaparin, 1635t
- Tiopronin, 435e-2, 1871
- Tiotropium, 1676, 1705
- TIP39, 2468
- Tipranavir, 1276f, 1280f
- TIPS. *See* Transjugular intrahepatic portosystemic shunt (TIPS)
- TIRAP, 145e-5, 145e-6f
- TIR domains, 145e-5, 145e-6f
- Tirofiban
 action of, 746f, 748–749
 adverse effects of, 727t, 749
 dosage of, 749
 genetic variation in response to, 277t, 743t
 indications for, 749
 for myocardial infarction, 1598t
 in PCI, 296e-1
 pharmacology of, 749t
- Tissue engineering, 92e-1
 future directions in, 92e-3–4
 isolation and growth of cells in, 92e-1
 level of complexity in, 92e-1–2, 92e-2f
 scaffolds for, 92e-1
 strategies for, 92e-2, 92e-3v
 vascularization and innervation in, 92e-1
- Tissue factor, 745
- Tissue factor (TF), 401, 401f
- Tissue factor pathway inhibitor
 antithrombotic actions of, 402, 402f, 750
 for sepsis/septic shock, 1758
- Tissue invasion, by pathogens, 145e-7–8
- Tissue nonspecific alkaline phosphatase (TNSALP), 426e-5
- Tissue plasminogen activator (tPA)
 for acute limb ischemia, 1646
 arterial thrombotic disease and, 744
 contraindications to, 1605
 in fibrinolysis, 402–403, 402f
 for myocardial infarction, 1605
 recombinant. *See* Alteplase (rtPA)
- Tissue stem cells, 453
- Tissue thromboplastin inhibition test, 406
- Tissue transglutaminase, 372e-24t, 2763t
- Tissue tropism, of pathogens, 145e-8–9
- Titanium dioxide, 1691
- Titin, 265e-5
- Tivantinib, 551
- Tizanidine, 473e-9t, 473e-10t, 2660, 2672
- TK gene, 91e-4
- TLC (total lung capacity), 306e-1f, 306e-2, 306e-2f, 306e-5f
- TLR7 gene, in HIV infection, 1240t
- TLR (toll-like receptor) pathway deficiencies, 2106
- TLRs. *See* Toll-like receptors (TLRs)
- T lymphocytes. *See* T cell(s)
- TMC207 (bedaquiline), 205e-7
- TMP-SMZ. *See* Trimethoprim-sulfamethoxazole (TMP-SMZ)
- TNF. *See* Tumor necrosis factor (TNF)
- TNF-R1 gene, 372e-8t
- TNFRSF11A/B genes, 426e-1, 2215
- TNM staging, 470
 of appendiceal NETs, 560, 561t
 of bladder cancer, 575, 576f
 of bone sarcoma, 119e-3, 119e-3t
 of breast cancer, 526, 527t
 of colorectal cancer, 541–542, 542f
 of head and neck cancer, 504, 504f
 of hepatocellular carcinoma, 546
 of lung cancer, 513–514, 514f, 516t
 of pancreatic cancer, 555, 556f
 of pNETs, 560, 560t
 of prostate cancer, 582, 582f, 582t
 of soft tissue sarcoma, 119e-2, 119e-2t
- TNSALP (tissue nonspecific alkaline phosphatase), 426e-5
- Tobacco grower's lung, 1681t
- Tobacco use. *See also* Smoking
 global burden of disease caused by, 17
 types of, 2730–2731
 in women, 6e-5
- Tobramycin
 action of, 930, 931t
 adverse effects of, 942
 for community-acquired pneumonia, 808t
 for health care-associated pneumonia, 767t